ArticleInfection and immunity2015
Anti-Pseudomonas aeruginosa IgY Antibodies Induce Specific Bacterial Aggregation and Internalization in Human Polymorphonuclear Neutrophils.
Article in Infection and immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- Intravenous anti-P. aeruginosa IgY antibodies increase bacterial concentration in porcine septic shock with bacteremia.Intensive care medicine experimental · 2026Article
- IgY technology (egg yolk antibodies) in respiratory medicine: applications and future prospects.Archives of microbiology · 2026Review
- Quorum Sensing Inhibition and Virulence Factor Attenuation inJournal of pharmacopuncture · 2025Article
- Immune system dynamics in response to Pseudomonas aeruginosa biofilms.NPJ biofilms and microbiomes · 2025Review
- A systematic review of the avian antibody (IgY) therapeutic effects on human bacterial infections over the decade.Antibody therapeutics · 2025Review
- Neutrophils, not macrophages, aid phage-mediated control of pulmonaryFrontiers in immunology · 2025Article
- Polyclonal anti-whole cell IgY passive immunotherapy shields against P. aeruginosa-induced acute pneumonia and burn wound infections in murine models.Scientific reports · 2024Article
- IgY antibodies: The promising potential to overcome antibiotic resistance.Frontiers in immunology · 2023Review
- Immune Response to Biofilm Growing PulmonaryBiomedicines · 2022Review
- Chicken IgY reduces the risk ofFrontiers in microbiology · 2022Article
- Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii pneumonia infection.Scientific reports · 2021Article
- Immunoglobulin Y for Potential Diagnostic and Therapeutic Applications in Infectious Diseases.Frontiers in immunology · 2021Review
- Immune Responses toFrontiers in immunology · 2021Review
- Production and characteristics of a novel chicken egg yolk antibody (IgY) against periodontitis-associated pathogens.Journal of oral microbiology · 2020Article
- IgY - turning the page toward passive immunization in COVID-19 infection (Review).Experimental and therapeutic medicine · 2020Review
- Immunotherapy with IgY Antibodies toward Outer Membrane Protein F Protects Burned Mice againstJournal of immunology research · 2020Article
- The protective effects of antigen-specific IgY on pyocyanin-treated human lymphoma Raji cells.F1000Research · 2019Article
- IgY antibodies for the immunoprophylaxis and therapy of respiratory infections.Human vaccines & immunotherapeutics · 2019Review
- Anti-lipopolysaccharide egg yolk antibodies enhance the phagocytosis of mammalian phagocytes.Biology open · 2018Article
- Achromobacter Species Isolated from Cystic Fibrosis Patients Reveal Distinctly Different Biofilm Morphotypes.Microorganisms · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymorphonuclear neutrophils (PMNs) are essential cellular constituents in the innate host response, and their recruitment to the lungs and subsequent ubiquitous phagocytosis controls primary respiratory infection. Cystic fibrosis pulmonary disease is characterized by progressive pulmonary decline governed by a persistent, exaggerated inflammatory response dominated by PMNs. The principal contributor is chronic Pseudomonas aeruginosa biofilm infection, which attracts and activates PMNs and thereby is responsible for the continuing inflammation. Strategies to prevent initial airway colonization with P. aeruginosa by augmenting the phagocytic competence of PMNs may postpone the deteriorating chronic biofilm infection. Anti-P. aeruginosa IgY antibodies significantly increase the PMN-mediated respiratory burst and subsequent bacterial killing of P. aeruginosa in vitro. The mode of action is attributed to IgY-facilitated formation of immobilized bacteria in aggregates, as visualized by fluorescence microscopy and the induction of increased bacterial hydrophobicity. Thus, the present study demonstrates that avian egg yolk immunoglobulins (IgY) targeting P. aeruginosa modify bacterial fitness, which enhances bacterial killing by PMN-mediated phagocytosis and thereby may facilitate a rapid bacterial clearance in airways of people with cystic fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.